Morgan Stanley Initiates Coverage On Myriad Genetics with Equal-Weight Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has initiated coverage on Myriad Genetics with an Equal-Weight rating and set a price target of $32.
September 19, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has initiated coverage on Myriad Genetics with an Equal-Weight rating and a price target of $32, indicating a neutral stance on the stock.
The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook, which may not significantly impact the stock price in the short term. The price target of $32 provides a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100